Should I Buy GANX? GANX 2026 Analysis

Should You Buy Gain Therapeutics Inc (GANX) Today? Analysis, Price Targets, and 2026 Outlook.

No data

Growth

Profitability

Efficiency

4 Analyst Rating

Wall Street analysts forecast GANX stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.890

Low

Averages

7.5

High

Current: 1.890

Low

Averages

7.5

High

Roth Capital

NULL -> Buy

upgrade

$6 -> $10

AI Analysis

2025-12-19

Reason

Roth Capital

Price Target

$6 -> $10

AI Analysis

2025-12-19

upgrade

NULL -> Buy

Reason

Roth Capital raised the firm's price target on Gain Therapeutics to $10 from $6 and keeps a Buy rating on the shares. The firm says GT-02287 demonstrated blood-brain barrier penetration and triggered a reduction in GluSph levels in the Phase 1b study. This offers "direct mechanistic evidence" for GCase target engagement, the analyst tells investors in a research note. Roth cites the data for the target increase.

BTIG

Buy

downgrade

$9 -> $5

2025-10-16

Reason

BTIG

Price Target

$9 -> $5

2025-10-16

downgrade

Buy

Reason

BTIG lowered the firm's price target on Gain Therapeutics to $5 from $9 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GANX

Unlock Now

GANX Should I Buy

GANX Should I Buy

Should You Buy Gain Therapeutics Inc (GANX) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

Growth

Profitability

Efficiency

People Also Watch